Project Details
Description
Project goal is to develop a prototype active immunotherapy to complement directly acting antiviral drugs in treatment of chronic hepatitis C, which would target and eliminate HCV-infected cells, specifically malignant (transformed) hepatocytes and lymphocytes. The immunotherapy will be based on a conserved HCV antigen nucleocapsid (Core) protein and tumor-associated antigen involved in the early events in hepatocarcinogenesis, human telomerase reverse transcriptase, presented by synthetic genes (HCV/TERT-DNA).
| Acronym | LIVE®VAC |
|---|---|
| Status | Finished |
| Effective start/end date | 1/12/18 → 28/02/21 |
| Links | https://www.rsu.lv/en/project/new-approach-active-immunotherapy-hepatitis-c-related-cancer-livervac |
Total Funding
- Latvian Council of Science: €200,000.00
Keywords
- hepatitis C
- hepatocellular carcinoma
- non-Hodgkin's B-cell lymphoma
- DNA vaccine
- TLR ligand
- checkpoint inhibitor
- mouse model
Field of Science
- 3.3 Health sciences
Smart Specialization Area
- Biomedicine, medical technologies and biotechnology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.